“Carcinoma de pulmón célula no pequeña: ¿hay diferencias por histología utilizando inmunoterapia?” - page 5

What factors may

impact outcomes with immune

checkpoint inhibitors?

Histology

PD-L1/other

immune

biomarkers

Mutational

status

Patient

characteristics

Introduction

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4 6,7,8,9,10,11,12,13,14,15,...21